ABEONA THERAPEUTICS INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
ABEONA THERAPEUTICS INC. (ABEO) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 12-month period ending 2022-12-31, per its 10-K filed 2024-03-18.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2024-03-18
- ABEONA THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2022-03-31 was 0.00%.
- ABEONA THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2021-09-30 was 0.00%.
- ABEONA THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2021-06-30 was 0.00%.
- ABEONA THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2021-03-31 was 0.00%.
- ABEONA THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2022 was 0.00%.
- ABEONA THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2021 was 0.00%.
- ABEONA THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2020 was 0.00%.
- ABEONA THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2019 was 0.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month |
|---|---|---|---|---|
| 2022-12-31 | 0.00% 10-K · filed 2024-03-18 | |||
| 2022-09-30 | 0.00% 10-Q · filed 2023-11-13 | |||
| 2022-06-30 | 0.00% 10-Q · filed 2023-08-08 | |||
| 2022-03-31 | 0.00% 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | 0.00% 10-K · filed 2023-03-29 | |||
| 2021-09-30 | 0.00% 10-Q · filed 2021-11-15 | 0.00% 10-Q · filed 2021-11-15 | ||
| 2021-06-30 | 0.00% 10-Q · filed 2021-07-28 | 0.00% 10-Q · filed 2021-07-28 | ||
| 2021-03-31 | 0.00% 10-Q · filed 2022-05-13 | |||
| 2020-12-31 | 0.00% 10-K · filed 2022-03-31 | |||
| 2020-09-30 | 0.00% 10-Q · filed 2021-11-15 | 0.00% 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | 0.00% 10-Q · filed 2021-07-28 | 0.00% 10-Q · filed 2021-07-28 | ||
| 2020-03-31 | 0.00% 10-Q · filed 2021-05-17 | |||
| 2019-12-31 | 0.00% 10-K · filed 2021-03-24 | |||
| 2019-09-30 | 0.00% 10-Q · filed 2020-11-09 | 0.00% 10-Q · filed 2020-11-09 | ||
| 2019-06-30 | 0.00% 10-Q · filed 2020-08-10 | 0.00% 10-Q · filed 2020-08-10 | ||
| 2019-03-31 | 0.00% 10-Q · filed 2020-05-06 | |||
| 2018-12-31 | 0.00% 10-K · filed 2020-03-16 | |||
| 2018-09-30 | 0.00% 10-Q · filed 2019-11-12 | 0.00% 10-Q · filed 2019-11-12 | ||
| 2018-06-30 | 0.00% 10-Q · filed 2019-08-09 | 0.00% 10-Q · filed 2019-08-09 | ||
| 2018-03-31 | 0.00% 10-Q · filed 2019-05-10 | |||
| 2017-12-31 | 0.00% 10-K · filed 2020-03-16 | |||
| 2016-12-31 | 0.00% 10-K · filed 2019-03-18 | |||
| 2014-09-30 | 0.00% 10-Q · filed 2014-11-14 | |||
| 2013-06-30 | 0.00% 10-Q · filed 2014-08-14 | |||
| 2012-09-30 | 0.00% 10-Q · filed 2012-11-14 | |||
| 2012-06-30 | 0.00% 10-Q · filed 2012-08-14 | |||
| 2011-09-30 | 0.00% 10-Q · filed 2012-11-14 | |||
| 2011-06-30 | 0.00% 10-Q · filed 2012-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |